Client News

Roquefort Therapeutics plc: Patent Filed – New Drug Class Targeting Midkine
Home / Client News / Roquefort Therapeutics plc: Patent Filed – New Drug Class Targeting Midkine

​Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company focused on early-stage opportunities in the biotechnology sector, is pleased to announce that the Company has filed its first composition of matter provisional patent application for a new class of RNA therapeutic drugs targeting Midkine.

In 2021 the Company entered into a collaboration with Professor Steve Wilton’s group at Murdoch University, Perth, Western Australia to design and test a novel series of gene silencing reagents, antisense oligonucleotides, targeting Midkine. These oligonucleotide drugs interfere with processing of the Midkine mRNA ultimately leading to reduced active Midkine protein produced in diseased tissues and tumours. Prof. Wilton is a pioneer in this gene silencing technology, having gained FDA approval for one of the first RNA therapeutic drugs of this style for the treatment of Duchenne’s Muscular Dystrophy.

https://www.londonstockexchange.com/news-article/ROQ/patent-filed-new-drug-class-targeting-midkine/15375533

OPEN AN ACCOUNT

If you are interested in opening an account with Optiva Securities, please fill in the details on the apply button.

CLIENT AREA

Please ensure that the information you entered is accurate, and that your “Caps Lock” key is set correctly.

Share This